WebBackground: Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. Methods: Characteristics of 812 consecutive solid cancer patients who received at least one cycle of ED monotherapy (pembrolizumab 400 mg Q6W or ... WebBrezplačna dostava ob naročilu nad 50 € O nas Kontakt Novice Moj račun. Domov; Knjige
Did you know?
WebJul 20, 2024 · Erika Rijavec received honoraria from Bristol-Myers Squibb. Paolo Spallarossa has consulting/advisory relationship with Incyte, Teva, Bristol-Myers Squibb and received honoraria from Incyte, Teva, and Servier. All other authors declare no conflicts of interest. Ethical approval. WebMar 23, 2024 · Journal Article Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non‐Small Cell Lung Cancer Patients Matteo Sarocchi, Francesco Grossi, Eleonora Arboscello, Andrea Bellodi, Carlo Genova, Maria Giovanna Dal Bello, Erika Rijavec, Giulia Barletta, Giovanni Rossi, Federica Biello ... Show more Author Notes
WebIndini, Alice ; Rijavec, Erika; Grossi, Francesco. / Trastuzumab Deruxtecan : Changing the Destiny of HER2 Expressing Solid Tumors. In: International Journal of Molecular … WebAU - Rijavec, Erika. AU - Grossi, Francesco. PY - 2024/4/30. Y1 - 2024/4/30. N2 - HER2 targeted therapies have significantly improved prognosis of HER2-positive breast and gastric cancer. HER2 overexpression and mutation is the pathogenic driver in non-small cell lung cancer (NSCLC) and colorectal cancer, however, to date, there are no approved ...
WebErika Rijavec is in Milan, Italy. Rijavec and is highly rated in 3 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer, Lung Cancer, EGFR … WebErika Rijavec's 125 research works with 1,805 citations and 11,038 reads, including: First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including …
WebDive into the research topics where Erika Rijavec is active. These topic labels come from the works of this person. Together they form a unique fingerprint. 1 Similar Profiles Non-Small Cell Lung Carcinoma Medicine & Life Sciences Nivolumab Medicine & Life Sciences Survival Medicine & Life Sciences Immunotherapy Medicine & Life Sciences
WebFrancesco Grossi, Erika Rijavec, Carlo Genova, Federica Biello, and Claudia Maggioni contributed to the interpretation of the data and revised the manuscript. All authors discussed the results and reviewed and approved the manuscript. Conflicts of Interest. nachtcafe youtube 2022WebJan 20, 2024 · Correspondence: Erika Rijavec, Email [email protected] Abstract: Rearrangement of anaplastic lymphoma kinase ( ALK ) gene is detected in … nacht carolWebNaslov: Sladkorna bolezen, naš izziv : delavnice in predavanja v okviru dogodka Sladkorna bolezen, naš izziv, Lendava in Prevalje, 30. 11. 2024 in 14. nachtclub annabellaWebAlice Indini 1, Erika Rijavec 1 and Francesco Grossi 2,* Citation: Indini, A.; Rijavec, E.; Grossi, F. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid … medic-center fürthWebErika Rijavec has received honoraria from Bristol Myers Squibb and Boehringer Ingelheim. Carlo Genova has received honoraria from Bristol Myers Squibb, Boehringer Ingelheim, AstraZeneca, Merck Sharp Dohme, Roche, and Advisory Board: Merck Sharp Dohme. Alice Indini has received honoraria from Bristol Myers Squibb, Merck Sharp Dohme, and … nachtclub altheimWebJan 20, 2024 · Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib . Authors Erika Rijavec 1 , … nachtcamera hurenWebArticles by Erika Rijavec on Muck Rack. Find Erika Rijavec's email address, contact information, LinkedIn, Twitter, other social media and more. medic center orthopädie nürnberg